In particular, ibrutinib is the first-in-class inhibitor of Bruton’s tyrosine kinase (BTK) that is now in clinical use for treatment of B-CLL patients as a category 1 agent in the relapsed/refractory disease [9,10,11]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.